By Monica Heger
This story was originally published Oct. 17.
Sequenom said this week that it has launched its noninvasive lab-developed sequencing-based test for Down syndrome in 20 US metropolitan areas and has published a clinical validation study for the test in the journal Genetics in Medicine.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.